Trial Profile
Study Phase II / III, multicenter, double-masked, randomized, parallel Group, with variations of dose, controlled to evaluate the efficacy and safety of NOVA22007 (eye cationic emulsion of Cyclosporine A (CSA) 00:05% and 0.1%) vs. vehicle in patients with vernal queratoconjonctivitis
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 12 Apr 2022
Price :
$35
*
At a glance
- Drugs Ciclosporin (Primary)
- Indications Allergic conjunctivitis
- Focus Therapeutic Use
- Sponsors Santen S.A.S.
- 08 Apr 2022 Status changed from recruiting to completed.
- 09 Sep 2014 New trial record